ProCE Banner Activity

Phase I/II EPCORE NHL-2 Trial Update: Epcoritamab + Rituximab/Lenalidomide in Follicular Lymphoma

Slideset Download
Conference Coverage

Epcoritamab + rituximab/lenalidomide resulted in high response rates in both first-line and R/R FL with no severe CRS events.

Released: December 17, 2022

Expiration: December 16, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen